Biotech Umeå Investment Day 2018 on February 1 at Grand Hôtel in Stockholm is a partnering event, for startups, investors and industrial partners within life science. Beside Lipum you can also meet other exciting life science companies from the top-ranked Umeå Biotech Incubator. In fact, there is an opportunity already on 31st of January 2018, 17:00-21:00 [...]
The European Molecular Biology Laboratory (EMBL) was founded more than 40 years ago to be a centre of excellence for Europe’s most talented young scientists in the life sciences. In the Alumni Impact Report 2017 companies co-founded by EMBL alumni are listed, among those Lipum AB and Prof Lennart Lundberg. Read the report here.
Seal of Excellence Certificate by European Commission In response to Lipums application ”Novel Target for Treatment of Chronic Inflammatory Diseases” for SME Instrument 2 funding by EU’s Horizon 2020 an international panel of independent experts scored it as a high-quality project proposal in a highly competitive evaluation process. The ”Seal of Excellence” certificate is issued for [...]
Learn more about our novel target for treatment of chronic inflammatory diseases. We will attend: BIO-Europe in Berlin, Nov 6-8 Nordic-American conference in New York, Nov 13-14 RESI meeting in New York, Nov 15 We will tell you more about Bile Salt-Stimulated Lipase (BSSL) and our ongoing development of a therapeutic antibody. Lipum has collected [...]
Lipum offer a new route for treatment of chronic inflammatory diseases. Meet with our CEO Einar Pontén at BIO-Europe 2017 in Berlin, Nov 6-8. We will tell you more on our novel target Bile Salt-Stimulated Lipase (BSSL) and our ongoing development of a therapeutic antibody for treatment of these diseases. Lipum has collected original research data [...]
We invite investors to join us in the development towards better treatment of chronic inflammations. Meet us and learn more at the 17th Annual Biotech in Europe Forum, Basel, Sept 26-27.
Lipum offer a new route for treatment of chronic inflammatory diseases such as rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Contact us and meet with our CEO Einar Pontén at Nordic Life Science Days 2017 in Malmö. A novel target molecule We will tell you more on our novel target bile salt-stimulated lipase (BSSL) and [...]
Rheumatism is an autoimmune disease that causes chronic inflammation and pain. The inflammation can break down cartilage, adjacent bones, tendons and arteries. Also eyes and other organs can be affected. About one percent of the population suffer of the disease. It is more common among women than men. Drug market for the disease is estimated to [...]
Lipum offer a new route for treatment of chronic inflammatory diseases such as rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Contact us and meet with our CEO Einar Pontén at the NLSDays 2017. We will tell you more on our novel target bile salt-stimulated lipase (BSSL) and our ongoing development of a therapeutic antibody [...]
Lipum AB is the assignee of a strong patent portfolio and the rights of the patent from the inventors and the results within the BSSL research have all been transferred to the company. The patent "New method for treatment of inflammatory diseases.", previously granted on most major markets, has now also been approved in Canada. [...]